Roy Fleischmann, MD, on the Safety Profile of Upadacitinib In Patients With RA

Rheumatology & Arthritis Learning Network
07/11/2023 23 min
Roy Fleischmann, MD, on the Safety Profile of Upadacitinib In Patients With RA

Listen "Roy Fleischmann, MD, on the Safety Profile of Upadacitinib In Patients With RA"

Descargar episodio Ver en sitio original

Episode Synopsis

Dr Fleischmann reviews a post hoc analysis of the SELECT phase 3 trial of upadacitinib in rheumatoid arthritis and the safety of JAK inhibitors among RA patients at risk for cardiovascular events.

More episodes of the podcast Rheumatology & Arthritis Learning Network

Dacre Knight, MD, on Hypermobility Syndromes 28/04/2025
Leonard Calabrese, DO, on Long COVID 01/01/2025
Misti Paudel, PhD, on Difficult-to-Treat Rheumatoid Arthritis 06/08/2024
Vikas Majithia, MD, and Ronald Butendieck, MD, on the Continuing Challenges of Gout 19/06/2024
Risk Factors for COVID-19 Reinfection Among Patients With Rheumatic Diseases 13/03/2024
Neal Birnbaum, MD, on the new CMS Rule on Prior Authorization 28/02/2024
Leonard Calabrese, DO, on the Nosology of Long COVID 21/02/2024
Elena Myasoedova, MD, PhD, on Extra-articular Manifestations of RA 20/11/2023
Matthew Baker, MD, on the Association of Osteoarthritis With Atopic Dermatitis 01/11/2023
SARS‐CoV‐2 Vaccination Among Immunocompromised Patients Helps Mental Health 12/10/2023
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA